GENERAL CLINICAL DOCUMENTATION AND …
HIMAA Practice Brief 1 – General Documentation & Information Requirements 5 of 42 December 2006 V.1.0 4.0 GLOSSARY The following is a list of terms, associated definitions and concepts used in this
Download GENERAL CLINICAL DOCUMENTATION AND …
Information
Domain:
Source:
Link to this page:
Documents from same domain
Reviewed articles The risk and consequences of …
www.himaa.org.au38 HEALTH INFORMATION MANAGEMENT JOURNAL Vol 38 No 1 2009 ISSN 1833-3583 (PRINT) ISSN 1833-3575 (ONLINE) Reviewed articles as ‘disease surveillance and prevention, economic burden-of-illness studies, public …
Corporate Governance Toolkit for small and …
www.himaa.org.auCorporate Governance Toolkit for small and medium enterprises: 2nd Edition April 2005
Related documents
A Framework for Pharmacist Development in ... - …
www.codeg.orgAbout CoDEG The Competency Development and Evaluation Group (CoDEG) is a collaborative network of developers and researchers, practitioners, specialist …
Career Information : No points are allocated for ten …
www.dut.ac.zaCareer Information Bachelor of Health Sciences in Clinical Technology . Location . ML Sultan Campus (B Block 2 nd Floor) Purpose of the programme The purpose of this qualification is to develop a learner to possess
COMMITTEE FOR MEDICINAL PRODUCTS FOR …
www.ema.europa.euIt clarifies the requirements for clinical documentation for abridged applications for orally inhaled formulations and variations/extensions to a marketing authorisation, and including both single active substance products
Guideline on clinical development of fixed …
www.ema.europa.euThis is the nd2 revision of the guideline on clinical development of fixed combination medicinal products containing two or more active substances within a single pharmaceutical form.
DEVELOPMENT SAFETY UPDATE REPORT - ICH
www.ich.orgThe Development Safety Update Report (DSUR) proposed in this guideline is intended to be a common standard for periodic reporting on drugs under development (including
MEDICINES CONTROL COUNCIL - mccza.com
www.mccza.comRegistration of Medicines Biosimilars . MEDICINES CONTROL COUNCIL. BIOSIMILAR MEDICINES QUALITY, NON-CLINICAL AND CLINICAL REQUIREMENTS
CLINICAL CONSIDERATIONS FOR EVALUATION OF …
www.who.intPage 4 of 8 2.4 Clinical development programme The applicant should provide in the PSF a tabulated summary of the clinical development programme, in one or more tables, in which critical parameters that may have changed